Evidence map›Paper›PMID 40002897›Full record

ArticleBiomedicines2025

Prognostic Value of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) Score in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab.

Zuzana Tomčová, Jana Obertová, Michal Chovanec, Zuzana Syčová-Milá, Katarína Štefániková, Eva Šlachtová, Monika Žák, Alexander Savka, Matej Hrnčár, Katarína Rejleková and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zuzana Tomčová2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Klenová 1, 833 10 Bratislava, Slovakia.
Jana Obertová2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Klenová 1, 833 10 Bratislava, Slovakia.
Michal Chovanec2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Klenová 1, 833 10 Bratislava, Slovakia.
Zuzana Syčová-Milá2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Klenová 1, 833 10 Bratislava, Slovakia.
Katarína ŠtefánikováDepartment of Oncology, East Slovak Cancer Institute, Rastislavova 43, 041 91 Košice, Slovakia.
Eva ŠlachtováDepartment of Oncology, East Slovak Cancer Institute, Rastislavova 43, 041 91 Košice, Slovakia.
Monika ŽákDepartment of Oncology, East Slovak Cancer Institute, Rastislavova 43, 041 91 Košice, Slovakia.
Alexander SavkaDepartment of Oncology, F. D. Roosevelt University General Hospital, Nám. Ľ. Svobodu 1, 975 17 Banská Bystrica, Slovakia.
Matej HrnčárDepartment of Oncology, F. D. Roosevelt University General Hospital, Nám. Ľ. Svobodu 1, 975 17 Banská Bystrica, Slovakia.
Katarína Rejleková2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Klenová 1, 833 10 Bratislava, Slovakia.
Patrik Palacka2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Klenová 1, 833 10 Bratislava, Slovakia.ORCID 0000-0003-4505-0952

Funding

Bristol-Myers Squibb (APC) NA
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

albuminblood countsmetastatic diseasenivolumabrenal cell carcinoma

Identifiers

PMID40002897
PMCPMC11852442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.